On Oct. 20, 2025, Anthropic announced a new service called Claude of Life Sciences that uses artificial intelligence (AI) in efforts to advance scientific discovery. This is the San Francisco-based tech company’s first formal entry into life sciences research.

Digital tools will allow researchers to use Claude to make new discoveries through literature reviews to developing hypotheses, analyzing data, drafting regulatory submission, Anthropic said.

Anthropic has developed a family of large language models through Claude. On Sept. 29, Anthropic launched its newest model, Caude Sonnet 4.5, which is “significantly better” at life sciences, including laboratory protocols. Previously, scientists used Claude of individual tasks, including writing codes for statistical analysis or summarizing papers.

“Now, our goal is to make Claude capable of supporting the entire process, from early discovery through to translation and commercialization,” the company said. “To do this, we’re rolling out several improvements that aim to make Claude a better partner for those who work in the life sciences, including researchers, clinical coordinators and regulatory affairs managers.” The company said the new Claude version is better at several life science tasks.

Anthropic is working with several involved in life sciences, including Benchling, PubMed, 10x Genomics and Synapse.or. Anthropic has also partnered with companies to help life sciences organizations adopt AI, including Caylent, KPMG, Deloitte and cloud providers AWS and Google Cloud, the company said.

“AI in R&D only works through an ecosystem,” Ashu Singhal, co-founder and president of Benchling, said in a newsrelease. “Anthropic is doing this right, bringing together the best technologies while putting access, governance, and interoperability first. For more than a decade, scientists have trusted us as the source of truth for experimental data and to modernize their workflows. Now we’re building AI that powers this next chapter of R&D.”

Anthropic, a public AI research and development company headquartered in San Francisco, was founded in 2021 by seven OpenAI leaders and researchers who left because of disagreements over safety policies.

.